(Q40241230)

18 September 2017

title

Design, synthesis and antitumor evaluation of a new series of N-substituted-thiourea derivatives (English)

1 reference

18 September 2017

5

Xu Shen

1 reference

18 September 2017

Jian Li

1

1 reference

18 September 2017

Jin-zhi Tan

2

1 reference

18 September 2017

Li-li Chen

3

1 reference

18 September 2017

Jian Zhang

4

1 reference

18 September 2017

Chang-lin Mei

6

1 reference

18 September 2017

Li-li Fu

7

1 reference

18 September 2017

Li-ping Lin

8

1 reference

18 September 2017

Jian Ding

9

1 reference

18 September 2017

Bing Xiong

10

1 reference

18 September 2017

Xi-shan Xiong

11

1 reference

18 September 2017

Hong Liu

12

1 reference

18 September 2017

Xiao-min Luo

13

1 reference

18 September 2017

Hua-liang Jiang

14

1 reference

18 September 2017

publication date

1 September 2006

1 reference

Acta Pharmacologica Sinica

18 September 2017

published in

1 reference

18 September 2017

volume

27

1 reference

18 September 2017

issue

9

1 reference

18 September 2017

page(s)

1259-1271

1 reference

Chemical inhibitors of protein kinases

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Signal transduction by receptors with tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Tyrosine kinase inhibitors: from rational design to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

EGF receptor in neoplasia and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the hum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

4-Anilinoquinazolines with Lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: syntheses, chemical and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Benzamides and benzamidines as specific inhibitors of epidermal growth factor receptor and v-Src protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Elucidating inhibitory models of the inhibitors of epidermal growth factor receptor by docking and 3D-QSAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Discovering novel chemical inhibitors of human cyclophilin A: virtual screening, synthesis, and bioassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

An all atom force field for simulations of proteins and nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

Protein tyrosine kinase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2006.00437.X

10.1111/J.1745-7254.2006.00437.X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

18 September 2017

1030846925

0 references

1 reference